Dataset from A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy
and safety of daprodustat administered three-times weekly compared to epoetin alfa, the
current standard of care. This study includes a 4 week Screening Period, a 52 week Treatment
Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62
weeks. Approximately 402 subjects will be randomized to receive either daprodustat three
times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.